TransMedics Group Inc

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

TMDX$93.79+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share amounts)

	Year Ended December 31,
	2023	2022	2021
Revenue:
Net product revenue	$176,069	$79,234	$29,657
Service revenue	65,554	14,225	605
Total revenue	241,623	93,459	30,262
Cost of revenue:
Cost of net product revenue	41,015	16,970	9,031
Cost of service revenue	46,515	11,217	72
Total cost of revenue	87,530	28,187	9,103
Gross profit	154,093	65,272	21,159
Operating expenses:
Research, development and clinical trials	36,055	26,812	22,304
Acquired in-process research and development expenses	27,212	—	—
Selling, general and administrative	119,553	69,897	38,283
Total operating expenses	182,820	96,709	60,587
Loss from operations	(28,727)	(31,437)	(39,428)
Other income (expense):
Interest expense	(10,791)	(3,726)	(3,874)
Other income (expense), net	12,847	(1,002)	(877)
Total other income (expense), net	2,056	(4,728)	(4,751)
Loss before income taxes	(26,671)	(36,165)	(44,179)
(Provision) benefit for income taxes	1,643	(66)	(36)
Net loss	$(25,028)	$(36,231)	$(44,215)
Net loss per share attributable to common stockholders, basic and diluted	$(0.77)	$(1.23)	$(1.60)
Weighted average common shares outstanding, basic and diluted	32,517,372	29,556,633	27,616,839

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.